Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Other Non Operating Income: 2021-2025

Historic Other Non Operating Income for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $2.0 million.

  • Arcutis Biotherapeutics' Other Non Operating Income fell 51.34% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 40.60%. This contributed to the annual value of $16.2 million for FY2024, which is 37.22% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Other Non Operating Income stood at $2.0 million, which was down 2.91% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Other Non Operating Income registered a high of $5.2 million during Q2 2024, and its lowest value of -$40,000 during Q4 2021.
  • Moreover, its 3-year median value for Other Non Operating Income was $2.7 million (2025), whereas its average is $3.2 million.
  • Per our database at Business Quant, Arcutis Biotherapeutics' Other Non Operating Income spiked by 8,400.00% in 2022 and then slumped by 59.92% in 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Other Non Operating Income (Quarterly) stood at -$40,000 in 2021, then skyrocketed by 8,400.00% to $3.3 million in 2022, then fell by 19.52% to $2.7 million in 2023, then climbed by 1.72% to $2.7 million in 2024, then tumbled by 51.34% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $2.1 million for Q2 2025, and $2.7 million during Q1 2025.